Diagnosis of *Pneumocystis carinii* pneumonia: specificity and sensitivity of polymerase chain reaction in comparison with immunofluorescence in bronchoalveolar lavage specimens

ENRICA TAMBURRINI, PAOLA MENCARINI, A. DE LUCA, G. MAIURO, G. VENTURA, A. ANTINORI, ADRIANA AMMASSARI, ELENA VISCONTI, L. ORTONA, ALESSANDRA SIRACUSANO*, ELENA ORTONA* and G. VICARI*

Department of Infectious Diseases, Università Cattolica and *Department of Immunology, Istituto Superiore Sanità, Rome, Italy

Summary. DNA amplification by the polymerase chain reaction (PCR) is a promising method for the detection of *Pneumocystis carinii* in immunosuppressed patients. The sensitivity and specificity of the PCR technique has been assessed in comparison with the immunofluorescence method (IF) on bronchoalveolar lavage fluid (BALF). Results correlated in 43 (78.8%) of 52 cases studied. *P. carinii* PCR gave positive results with BALF from all 32 patients found to have *P. carinii* pneumonia (PCP); IF gave positive results with 26 of them. PCR was more sensitive and as specific as IF. However, at the present time, we do not believe that it is clinically useful for detection of *P. carinii* in BALF samples. *P. carinii* DNA amplification by PCR should be reserved for testing IF-negative BALF samples from patients judged clinically to have PCP.

Introduction

Pneumocystis carinii pneumonia (PCP) is one of the most frequent opportunist infections in AIDS patients. Although its incidence is declining and its mortality rate is decreasing, PCP still represents a crucial event during AIDS disease.¹ The extensive use of prophylaxis has changed the clinical presentation of PCP.^{2–5} Thus, it is important to have a method for the detection of *P. carinii* infection in HIV-infected patients on prophylaxis, when micro-organisms in the bronchoalveolar lavage fluid (BALF) are very few and show some staining peculiarities, and the clinical features of PCP are unusual.^{2,6} Moreover, a rapid, sensitive and specific diagnostic technique is required for the detection of *P. carinii* infection in patients with only mild symptoms of respiratory failure.

Recently, Wakefield *et al.* have developed a highly specific and sensitive technique for the identification of *P. carinii* by polymerase chain reaction (PCR) amplification of DNA in BALF⁷ and induced sputum.⁸ A strong signal in the PCR (ethidium bromide and oligoblotting positive) was consistent with a diagnosis of PCP; a weak signal (oligoblotting positive alone) indicated subclinical pulmonary colonisation.⁹

The primary aim of our study was to assess the sensitivity, specificity, positive predictive value, nega-

tive predictive value and accuracy of the PCR technique on BALF as compared to the indirect immunofluorescence (IF) method for the detection of *P. carinii* infection in immunosuppressed patients. A secondary aim was to investigate the relationship between the result of a “quantitative” PCR for *P. carinii* and the clinical presentation of PCP.

Materials and methods

Patients and clinical specimens

BALF samples were obtained from 52 immunosuppressed patients (39 male, 13 female; age range 24–58 years) at the Department of Infectious Diseases, Università Cattolica, Rome; 48 had HIV infection, three were being treated for lymphoma and one was hypogammaglobulinaemic (with a selective deficit of IgA and IgM). Forty-nine patients underwent bronchoscopy for an acute respiratory illness (fever, cough, shortness of breath) with one or more of the following features: abnormal chest signs, arterial hypoxaemia, abnormal chest X-ray. Three HIV-infected patients underwent bronchoscopy to investigate the presence of a pulmonary Kaposi's sarcoma.

Bronchoalveolar lavage was performed by two different operators who used the same technique:¹⁰ 10 ml of lukewarm saline (NaCl 0.9%) were instilled

into the middle lobe and the lingula with an Olympus fibre-optic bronchoscope; after 60 s, a lavage sample was recovered corresponding to 50–65% of the instilled volume. BALF samples were processed for microbiological and cytological analysis and a sample was stored at -20°C until required for PCR.

Indirect immunofluorescence

Indirect immunofluorescence (IF) with monoclonal antibodies (MAbs) specific for antigens of the cyst wall (Monofluokit *P. carinii*, Diagnostics Pasteur, Paris, France) was performed according to the manufacturer's instructions. The dried smears were overlaid with 20 μl of trypsin and incubated at 37°C for 30 min in a humidified chamber. They were rinsed and then overlaid with 20 μl of anti-*P. carinii* mouse MAb. The slides were incubated at 37°C , rinsed and overlaid with 20 μl of fluorescein isothiocyanate-conjugated anti-mouse antibody. After a final rinse, the smears were examined by fluorescence microscopy. The IF test was considered to be positive if five or most cysts were detected on a smear.

P. carinii DNA amplification by PCR

Briefly, 20 μl of BALF samples were digested with proteinase K (Sigma; 0.5 mg/ml final concentration) in the presence of 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl_2 and SDS 0.25% for 2 h at 56°C . In 20 cases, phenol-chloroform extraction and ethanol precipitation¹¹ was also performed but no appreciable advantage was observed with this protocol and it was not used with the remaining 32 specimens; when this step was omitted, proteinase K was inactivated by heating the digested samples at 95°C for 10 min. A 45- μl volume of buffer containing 100 mM Tris-HCl (pH 8.3), 500 mM KCl, 15 mM MgCl_2 and gelatin 0.01% w/v was added; 5 μl of this mixture (equivalent to 1 μl of a clinical specimen) was used for DNA amplification. An oligonucleotide primer pair (pAZ 102-E and pAZ102-H), which amplifies a *P. carinii* DNA sequence of part of the gene coding for the large subunit of mitochondrial ribosomal RNA,^{7,12} was used. Oligonucleotides were synthesised at the Institute of Genetics, Università Cattolica, Rome. For amplification, 100 pmol of primers were used in a 100 μl volume of amplification buffer containing (final concentrations) 10 mM Tris-HCl, 50 mM KCl, 4 mM MgCl_2 , 0.2 mM dNTPs (Perkin Elmer-Cetus, Norwalk, CT, USA), Taq DNA polymerase (Perkin Elmer-Cetus) 2.5 units. A "hot start" technique was used and 38 cycles of 94°C for 90 s (denaturation), 55°C for 90 s (annealing) and 72°C for 2 min (extension), with a final extension at 72°C for 5 min, were performed in a thermal cycler (Perkin Elmer-Cetus).

A 5- μl volume of amplification solution was electrophoresed in an agarose 2% gel containing ethidium bromide 0.5 $\mu\text{g}/\text{ml}$ and the 346-bp amplification product was visualised with an ultraviolet transilluminator.

The amplification product was also blotted on to a nylon filter (Hybond N, Amersham, Sydney, Australia) and hybridised with a ^{32}P 5'-end-labelled oligonucleotide specific for human derived *P. carinii*.^{7,13} After high stringency washes, the product was visualised by overnight exposure to an XAR-5 film (Eastman Kodak, Rochester, NY) at -70°C with intensifying screens.

The sensitivity of the technique was tested by adding serial dilutions of murine *P. carinii* organisms to a PCR-negative BALF. The cyst:trophozoite ratio of the preparation was found to be 1:10 based on Giemsa staining and the average number of nuclei was $1.44 \times 10^6/\mu\text{l}$. Samples were processed as above, and the amplification product was electrophoresed on an agarose 2% gel containing ethidium bromide. The amplification product was blotted and hybridised with an anti-sense oligonucleotide (5'-CCA GCT ATA TCC TAG TCC GA-3') specific for both rat and human derived *P. carinii*.¹³ A signal was detectable for samples containing ≥ 10 nuclei/ μl of BALF by ethidium bromide and ≥ 1 nucleus/ μl of BALF by oligoblotting.

All pre-PCR steps were performed in a laminar flow cabinet, and laboratory procedures to avoid contamination were strictly applied. All experimental stages were performed in duplicate; multiple negative controls (including bronchoscope washing fluid) were included in each amplification run.

Statistical methods

Sensitivity, specificity, positive predictive value, negative predictive value and accuracy of PCR and IF results for the detection of *P. carinii* in BALF were calculated from a 2×2 table.¹⁴ The statistical significance of differences in the sensitivities and specificities of the two methods was calculated by McNemar's test.¹⁵

Results

On the basis of clinical data, response to treatment and results of laboratory investigations (including IF for *P. carinii* and microbiological and cytological investigations on BALF and post-mortem lung samples), the 52 patients were classified as follows: group A—26 immunosuppressed patients (24 HIV-positive and two HIV-negative) with *P. carinii* pneumonia diagnosed by IF and response to treatment; group B—four patients (three HIV-positive and one HIV-negative) with *P. carinii* pneumonia diagnosed by response to treatment but IF negative; group C—two HIV-positive patients with *P. carinii* pneumonia diagnosed by autopsy but IF negative and response to treatment not evaluable; group D—17 patients (16 HIV-positive and one HIV-negative) without *P. carinii* pneumonia, negative by IF, with no response to treatment and an alternative aetiological cause for the

Table I. DNA amplification and immunofluorescence for *P. carinii* in BALF; comparison with response to treatment

Classification of patients	Number of patients	IF result	Autopsy	Response to treatment	Number of BALF samples with PCR result		
					EB+ OB+	EB- OB+	EB- OB-
Group A	26	+	...	+	21	5	0
Group B	4	-	...	+	3	1	0
Group C	2	-	positive	NE	2	0	0
Group D	17	-	negative*	-	0	0	17
Group E	3	-	NA†	-	0	3	0

NA, not available; NE, not evaluable; EB, ethidium bromide; OB, oligoblotting.

*Ten patients alive.

†One patient alive.

Table II. DNA amplification and immunofluorescence for *P. carinii* on BALF of 32 patients with PCP: influence of specific prophylaxis

Treatment	Number of cases	IF +	Number of BALF samples with PCR result		
			EB+ OB+	EB- OB+	EB- OB-
Episode I	28	...	...	...	...
No prophylaxis	22	17	21	1	0
Prophylaxis					
AP	1	0	0	1	0
CTX	1	1	0	1	0
D+P	4	4	3	1	0
total	...	22	24	4	0
Episode II	4	...	...	...	...
AP	3	3	2	1	0
D+P	1	1	0	1	0
total	...	4	2	2	0
Total	32	26	26	6	0

AP, aerosolised pentamidine 300 mg every 4 weeks; CTX, co-trimoxazole one double strength tablet every second day; D+P, dapsone 100 mg weekly plus pyrimethamine 25 mg twice weekly.

respiratory disease; group E—three patients (HIV-positive) with negative IF and response to non-specific treatment (table I). Thus, 32 patients (groups A+B+C) were ultimately found to have PCP; 28 of them experienced a first episode of PCP (six were on prophylaxis), and the remaining four experienced a relapse 3–16 months after initial PCP diagnosis. Of the 20 patients judged to be free of PCP (groups D+E), 13 were on specific prophylaxis.

The results of *P. carinii* DNA amplification are reported in table I. Samples from all patients with PCP gave positive results by *P. carinii* DNA amplification by PCR (by oligoblotting, with or without ethidium bromide); samples from 17 patients without PCP gave negative results by PCR (both ethidium bromide and oligoblotting). Samples from three patients judged to be free of PCP gave positive results by PCR after oligoblotting. The first of these patients died from a heroin overdose and autopsy was not available; however, pulmonary disease was attributed to *Mycobacterium tuberculosis* (identified on BAL) and disseminated *Staphylococcus aureus* infection with lung micro-abscesses. The second patient died from respiratory and myocardial failure probably due to *M. tuberculosis*, 4 months after BAL; he was receiving anti-*P. carinii* prophylaxis with co-trimoxazole (one double-strength tablet every second day); autopsy not

authorised. The third patient, an intravenous drug abuser and a smoker (> 25 cigarettes daily) who suffered from recurrent episodes of bacterial pneumonia, remained alive; 10 months after BAL, a chest X-ray showed a pattern of chronic bronchitis; subsequently feeling well and on PCP prophylaxis with pyrimethamine (50 mg weekly) and dapsone (50 mg daily), her CD4+ cell count was 138/mm³.

In table II, *P. carinii* DNA amplification (PCR) results on the BALF samples from the 32 patients with PCP are related to the clinical data and *P. carinii* prophylaxis. Including the three immunosuppressed patients without HIV infection, 22 patients experienced PCP without primary prophylaxis; BALF samples from 21 (95.4%) gave positive PCR results by ethidium bromide and oligoblotting and one gave a positive result by oligoblotting alone. Ten HIV patients experienced PCP on prophylaxis (aerosolised pentamidine in four cases, co-trimoxazole in one and pyrimethamine+dapsone in five) as reported by Antinori *et al.*¹⁶ BALF samples from five patients (50%) gave positive PCR results by ethidium bromide and oligoblotting and five by oligoblotting alone.

Results obtained by IF and by PCR correlated in 43 (78.8%) of 52 cases studied; discrepant results included nine IF-negative BALF samples (six from patients with PCP and three from patients without

Table III. Diagnostic value of DNA amplification and immunofluorescence on BALF of patients with PCP

Criterion	IF	PCR	
		EB+ OB+	OB+ alone
Sensitivity	81.2	81.2	100
Specificity	100	100	85
Positive predictive value	100	100	91.4
Negative predictive value	76.9	76.9	100
Accuracy	88.5	88.5	94.2

PCP) that gave positive results by PCR; no specimen was IF-positive and PCR-negative.

The sensitivity, specificity, positive predictive value, negative predictive value and accuracy of IF and PCR for detection of *P. carinii* in BALF specimens from immunosuppressed patients are shown in table III. PCR with oligoblotting was significantly more sensitive than IF ($p = 0.031$). The specificity of PCR did not differ significantly from that of IF ($p = 0.25$).

Ethidium bromide staining detected a large number of samples that gave positive results by oligoblotting with a sensitivity of 74.3%, specificity of 100%, a positive predictive value of 100%, a negative predictive value of 65.4% and an accuracy of 82.7%.

Discussion

The choice of a diagnostic test is based on multiple factors, including the patient population, the volume of specimens being tested by the laboratory and the level of technical expertise required. Recently, Wakefield *et al.*^{7,8} were able to detect *P. carinii* by PCR amplification of specific DNA in specimens (BALF and induced sputum) that were negative by silver staining. The amplification method is likely to be more efficient than IF, which requires a minimum number of *P. carinii* to give a positive result,¹⁷ but results are still not conclusive. Indeed, Lipschik *et al.*¹⁸ reported that PCR was not significantly better than the conventional staining methods in BALF. PCR for *P. carinii* has been shown to be specific without cross-amplification of non-specific DNA.^{7,8,18} Moreover, Peters *et al.*⁷ suggested that a "strong" PCR signal was consistent with clinical diagnosis of PCP in immunosuppressed patients.

Our study confirmed that PCR was a very sensitive method for detection of *P. carinii*, giving positive results in all cases considered to have PCP. Negative controls (including bronchoscope washing fluid) performed with each PCR run, clearly showed that the method was very specific for *P. carinii*. For the PCR technique to be implemented in a routine diagnostic laboratory, the procedure needs to be improved in convenience and processing time. Our current protocol does not include DNA extraction with phenol-chloroform and precipitation with ethanol; the specimens are

processed in a maximum of 2.5 h and conclusive results may be achieved in 24–30 h; this procedure minimises the risk of sample contamination.

The "quantification" of PCR was performed by a limiting dilution technique with an external murine *P. carinii* standard. Digestion and amplification conditions were the same for standards and specimens. This allowed us to carry out a semi-quantitative determination of the number of nuclei present in 1 μ l of BALF. A signal detectable by both ethidium bromide and oligoblotting denotes the presence of a number of *P. carinii* nuclei ≥ 10 ; clinical specimens that gave positive results by oligoblotting alone contain 1–10 nuclei. The concentration of organisms in BALF may vary according to the bronchoalveolar lavage procedure used; nevertheless, throughout the study, samples were collected by the same technique and the variation of the recovered sample: instilled volume ratio was minimal. Our results suggest that a positive PCR test (by ethidium bromide and oligoblotting) is less powerful in the diagnosis of *P. carinii* pneumonia than that reported by Peters *et al.*⁹ A different study population could explain this observation. Amplification for *P. carinii* visible by both ethidium bromide and oligoblotting is consistent with clinical disease in immunosuppressed patients without prophylaxis (21 of 22 cases, table II). However, samples from five of 10 immunosuppressed patients who experienced PCP during specific prophylaxis may have given positive results by oligoblotting alone because a lower number of *P. carinii* organisms was present. Samples from three immunosuppressed patients with pneumonia probably not caused by *P. carinii* showed positive *P. carinii* DNA amplification by oligoblotting only. We believe that these three clinical specimens are not false positive results. Sub-clinical colonisation by *P. carinii* may occur in severely immunosuppressed patients.^{9,18,19} Transmission of *P. carinii* from one patient to another could occur during hospitalisation and room-sharing, or from close contact in the community. Furthermore, two other patients, with previous PCP, were PCR-negative for *P. carinii*. These observations, combined with the failure to detect *P. carinii*-specific DNA in post-mortem lungs from non-immunosuppressed individuals,²⁰ suggest that recurrent PCP may occur from re-infection rather than reactivation of latent organisms; also, sporadic PCP may occur in immunosuppressed HIV-negative^{21,22} patients or in adults without predisposing illnesses.²³

In conclusion, we compared the presence of *P. carinii* in BALF as detected by IF technique, with amplification of *P. carinii* DNA by PCR; results correlated in 78.8% of cases studied. PCR was highly sensitive for the detection of *P. carinii* and detected *P. carinii* more efficiently than IF. The specificity of the two techniques was quite high, particularly in immunosuppressed patients with PCP. Nevertheless PCR has several technical disadvantages and, currently, we do not believe that it is clinically useful for the routine

detection of *P. carinii* in BALF. In our opinion, *P. carinii*-specific DNA amplification should be used only to test IF-negative BALF samples from patients judged clinically to have PCP. The next step will be to improve the sensitivity (and thus the predictive value) of ethidium bromide staining; preliminary results (unpublished data) suggest that a "nested" PCR could be almost as sensitive and specific as oligoblotting for the detection of *P. carinii*. With future improvements in convenience and processing time, PCR could

become the most reliable method of detecting *P. carinii* in non-invasive specimens, such as induced sputum. *P. carinii* DNA amplification by PCR may be a valuable epidemiological tool in the initiation and monitoring of PCP chemoprophylaxis.

This work was supported by a grant from the AIDS project (1992) (n. 722.5.26), Istituto Superiore di Sanità, Ministero della Sanità, Rome, Italy. We are grateful to Dr M. Genuardi (Institute of Genetics, Università Cattolica, Rome) for technical support and very helpful discussions.

References

- Peters BS, Beck EJ, Coleman DG *et al.* Changing disease patterns in patients with AIDS in a referral centre in the United Kingdom: the changing face of AIDS. *BMJ* 1991; **302**: 203–207.
- Jules-Elysee KM, Stover DE, Zaman MB, Bernard EM, White DA. Aerosolized pentamidine: effect on diagnosis and presentation of *Pneumocystis carinii* pneumonia. *Ann Intern Med* 1990; **112**: 750–757.
- Montgomery AB. *Pneumocystis carinii* pneumonia prophylaxis: past, present and future. *AIDS* 1992; **6**: 227–228.
- Raviglione MC. Extrapulmonary pneumocystosis: the first 50 cases. *Rev Infect Dis* 1990; **12**: 1127–1138.
- Sparling TG, Dong SR, Hegedus C, Burdge DR. Aerosolized pentamidine and disseminated infection with *Pneumocystis carinii*. *Ann Intern Med* 1989; **111**: 442.
- Levine SJ, Masur H, Gill VJ *et al.* The effects of aerosolized pentamidine prophylaxis on the diagnosis of *Pneumocystis carinii* pneumonia by induced sputum examination in patients infected with the human immunodeficiency virus. *Am Rev Resp Dis* 1991; **144**: 760–764.
- Wakefield AE, Pixley FJ, Banerji S *et al.* Detection of *Pneumocystis carinii* with DNA amplification. *Lancet* 1990; **336**: 451–453.
- Wakefield AE, Guiver L, Miller RF, Hopkin JM. DNA amplification on induced sputum samples for diagnosis of *Pneumocystis carinii* pneumonia. *Lancet* 1991; **337**: 1378–1379.
- Peters SE, Wakefield AE, Banerji S, Hopkin J. Quantification of the detection of *Pneumocystis carinii* by DNA amplification. *Mol Cell Probes* 1992; **6**: 115–117.
- Kleeh H, Pohl W (eds). Technical recommendations and guidelines for bronchoalveolar lavage (BAL): report of the European Society of Pneumology task group on BAL. *Eur Respir J* 1989; **2**: 561–585.
- Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual. Cold Spring Harbor, NY, Cold Spring Harbor Laboratory Press. 1989.
- Wakefield AE, Hopkin JM, Burns J, Hipkiss JB, Stewart TJ, Moxon ER. Cloning of DNA from *Pneumocystis carinii*. *J Infect Dis* 1988; **158**: 859–862.
- Sinclair K, Wakefield AE, Banerji S, Hopkin J. *Pneumocystis carinii* organisms derived from rat and human hosts are genetically distinct. *Mol Biochem Parasitol* 1991; **45**: 183–184.
- Sackett DL, Haynes RB, Guyatt GH, Tugwell P. The interpretation of diagnostic data. In: Sackett DL, Haynes RB, Guyatt GH, Tugwell P (eds) *Clinical epidemiology: a basic science for clinical medicine*. Boston/Toronto/London, Little, Brown and Company. 1991: 69–152.
- Daly LE, Bourke GJ, McGilvray J. Confidence intervals and hypothesis tests: two-group comparisons. In: Daly LE, Bourke GJ, McGilvray J (eds) *Interpretation and uses of medical statistics*, 4th edn. Oxford, Blackwell Scientific Publications. 1991: 102–138.
- Antinori A, Murri R, Tamburrini E, De Luca A, Ortona L. Failure of low-dose dapsone-pyrimethamine in primary prophylaxis of *Pneumocystis carinii* pneumonia. *Lancet* 1992; **340**: 788.
- Hopewell PC. *Pneumocystis carinii* pneumonia. Current concepts. In: Sande MA, Volberding PA (eds) *The medical management of AIDS*. Philadelphia, WB Saunders Company. 1992: 261–283.
- Lipschik GY, Gill VJ, Lundgren JD *et al.* Improved diagnosis of *Pneumocystis carinii* infection by polymerase chain reaction on induced sputum or blood. *Lancet* 1992; **340**: 203–206.
- Blumenfeld W, McCook O, Holodniy M, Katzenstein DA. Correlation of morphologic diagnosis of *Pneumocystis carinii* with the presence of pneumocystis DNA amplified by the polymerase chain reaction. *Mod Pathol* 1992; **5**: 103–106.
- Peters SE, Wakefield AE, Sinclair K, Millard PR, Hopkin J. A search for *Pneumocystis carinii* in post-mortem lungs by DNA amplification. *J Pathol* 1992; **166**: 195–198.
- Goesch TR, Gotz G, Stellbrinck KH, Albrecht H, Weh HJ, Hossfeld DK. Possible transfer of *Pneumocystis carinii* between immunodeficient patients. *Lancet* 1990; **336**: 627.
- Chave J-P, David S, Wauters J-P, Van Melle G, Francioli P. Transmission of *Pneumocystis carinii* from AIDS patients to other immunosuppressed patients: a cluster of *Pneumocystis carinii* pneumonia in renal transplant recipients. *AIDS* 1991; **5**: 927–932.
- Jacobs JL, Libby DM, Winters RA *et al.* A cluster of *Pneumocystis carinii* pneumonia in adults without predisposing illnesses. *N Engl J Med* 1991; **324**: 246–250.